Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track record of the firm behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 115,000 members, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS investors have turned bullish on Allergan
Botox maker Allergan has returned to its former glory, recapturing five-star status after dropping as low as three stars. Allergan’s long list of competitors includes Merck
Recent forays into different sectors of the medical aesthetics market also have investors handicapping new revenue opportunities for Allergan. Eyeing the $3.7 billion mascara market dominated by the likes of Revlon and Estee Lauder
The Motley Fool Income Investor service scours the market for solid investments paying investors money to hold shares, such as selections Pfizer and J&J. See which dividend paying firms the team is recommending today with a free 30 day trial.
Fool contributor Dave Mock recently upgraded his Pez dispenser with cherry flavor. He owns shares of Pfizer and Johnson & Johnson and is the author of The Qualcomm Equation. Pfizer is also an Inside Value recommendation. The Fool's disclosure policy holds the world's largest collection of bobble-heads.